Eisai, Versatem In Development Agreement For Small-Molecule Drug
This article was originally published in PharmAsia News
Executive Summary
Eisai has agreed with U.S.-based Versatem to collaborate on developing small-molecule drugs based on the U.S. firm's VS-507 (salinomycin) for targeting cancer stem cell.